PMID- 30008464
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1674-8301 (Print)
IS  - 2352-4685 (Electronic)
IS  - 1674-8301 (Linking)
VI  - 32
IP  - 4
DP  - 2018 Jul 23
TI  - Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation 
      and promotes uterine arteriole remodeling without impairing rat fetal 
      development.
PG  - 288-297
LID - 10.7555/JBR.32.20180039 [doi]
AB  - Preeclampsia is associated with over-activation of the innate immune system in 
      the placenta, in which toll-like receptor 4 (TLR4) plays an essential part. With 
      their potent anti-inflammatory effects, statins have been suggested as potential 
      prevention or treatment of preeclampsia, although evidence remains inadequate. 
      Herewith, we investigated whether pravastatin could ameliorate preeclampsia-like 
      phenotypes in a previously established lipopolysaccharide (LPS)-induced rat 
      preeclampsia model, through targeting the TLR4/NF-kappaB pathway. The results showed 
      that pravastatin reduced the blood pressure [maximum decline on gestational day 
      (GD) 12, (101.33+/-2.49) mmHg vs. (118.3+/-1.37) mmHg, P<0.05] and urine protein 
      level [maximum decline on GD9, (3,726.23+/-1,572.86) mug vs. (1,991.03+/-609.37) mug, 
      P<0.05], which were elevated following LPS administration. Pravastatin also 
      significantly reduced the rate of fetal growth restriction in LPS-treated rats 
      (34.10% vs. 8.99%, P<0.05). Further pathological analyses suggested a restoration 
      of normal spiral artery remodeling in preeclampsia rats by pravastatin treatment. 
      These effects of pravastatin were associated with decreased TLR4/NF-kappaB protein 
      levels in the placenta and IL-6/MCP-1 levels in serum. Additionally, no obvious 
      abnormalities in fetal liver, brain, and kidney were found after administration 
      of pravastatin. These results provide supportive evidence for use of pravastatin 
      in preventing preeclampsia.
FAU - Yang, Mu-Yi
AU  - Yang MY
AD  - Drum Tower Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu 
      210008, China.
FAU - Diao, Zhen-Yu
AU  - Diao ZY
AD  - Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Wang, Zhi-Yin
AU  - Wang ZY
AD  - Drum Tower Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu 
      210008, China.
FAU - Yan, Gui-Jun
AU  - Yan GJ
AD  - Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Zhao, Guang-Feng
AU  - Zhao GF
AD  - Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Zheng, Ming-Ming
AU  - Zheng MM
AD  - Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Dai, An-Yi
AU  - Dai AY
AD  - Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Dai, Yi-Min
AU  - Dai YM
AD  - Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing 
      University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Hu, Ya-Li
AU  - Hu YL
AD  - Drum Tower Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu 
      210008, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Biomed Res
JT  - Journal of biomedical research
JID - 101551157
PMC - PMC6117606
OTO - NOTNLM
OT  - arteriole remodeling pravastatin
OT  - fetal development
OT  - preeclampsia
OT  - toll-like receptor 4
EDAT- 2018/07/17 06:00
MHDA- 2018/07/17 06:01
PMCR- 2018/07/26
CRDT- 2018/07/17 06:00
PHST- 2018/07/17 06:00 [pubmed]
PHST- 2018/07/17 06:01 [medline]
PHST- 2018/07/17 06:00 [entrez]
PHST- 2018/07/26 00:00 [pmc-release]
AID - 10.7555/JBR.32.20180039 [doi]
PST - ppublish
SO  - J Biomed Res. 2018 Jul 23;32(4):288-297. doi: 10.7555/JBR.32.20180039.